Abstract 2200
Background
Bone metastases (BM) are common in patients with solid tumours, especially breast, prostate and lung cancer. Patients with BM may experience skeletal-related events (SRE) including pathological fractures and spinal cord compression. Bisphosphonates and denosumab, known as SRE preventive agents (SPA), are indicated for patients with BM and are recommended by ESMO guidelines. However, data on the clinical use of these agents are lacking. The aim of this study was to estimate the proportion of SPA- and SRE-naïve patients receiving SPA treatments at SRE preventive doses following BM diagnosis.
Methods
Adult patients with solid tumours, a record of BM and no record of SPA treatment or an SRE before the first-recorded BM were identified from March 2011 to June 2016 in the Danish National Patient Registry or Danish Cancer Registry. The proportion of patients receiving hospital-administered SPA, identified via the Health Services Database of the Central Denmark Region, was calculated over the 6-month period after their first-recorded BM diagnosis along with the 95% confidence interval (CI). Follow-up was until death or December 31, 2016.
Results
A total of 2,556 eligible patients were included (m/f 1501/1055; median age 70 years (IQR 63–77). SPA treatment was recorded for 822 (32%) patients, mainly before the development of an SRE (86%, n = 706), in contrast to post-SRE (14%, n = 116). Across all solid tumours, a greater proportion of younger than older patients received SPA treatment. Receipt of SPA before an SRE varied by cancer site: lung (50%, 95% CI 46%–54%), breast (42%, 95% CI 37%–47%), prostate (3%, 95% CI 2%–5%), and other solid tumours (20%, 95% CI 18%–23%). Median [IQR] time from first-recorded BM diagnosis to first SPA before an SRE also varied by cancer site: breast (22 [7, 51] days), lung (6 [3, 26] days), prostate (43 [17, 57] days) and other solid tumours (24 [5, 44] days).
Conclusions
In this descriptive study, variations in the use of SPA for SRE prevention in routine clinical settings were observed across different solid tumours, warranting further cancer-specific investigations while accounting for patients’ characteristics.
Clinical trial identification
Amgen study 20160169.
Editorial acknowledgement
Legal entity responsible for the study
Amgen (Europe) GmbH.
Funding
Amgen (Europe) GmbH through an institutional grant; administered by Aarhus University.
Disclosure
J. Acquavella: Shareholder / Stockholder / Stock options; JA retired from Amgen in 2014. A.M. Seesaghur: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen; Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. R.K. Hernandez: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. V. Ehrenstein: Full / Part-time employment; VE is a salaried employee of Aarhus University and has nothing to declare. All other authors have declared no conflicts of interest.
Resources from the same session
5995 - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: Poster Display session 1
Resources:
Abstract
2961 - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma
Presenter: Weiping Liu
Session: Poster Display session 1
Resources:
Abstract
5771 - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center
Presenter: Vadim Lesan
Session: Poster Display session 1
Resources:
Abstract
1165 - Risk factors for Bacteremia-Associated Mortality of Aeromona sobria in Hematologic Malignancies
Presenter: Gabriel De la Cruz-Kú
Session: Poster Display session 1
Resources:
Abstract
5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study
Presenter: Hyunkyung Park
Session: Poster Display session 1
Resources:
Abstract
1886 - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care
Presenter: Severine Coquerelle
Session: Poster Display session 1
Resources:
Abstract
1940 - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1946 - Is bone marrow examination indispensible in chronic myeloid Leukemia at diagnosis ?
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India
Presenter: Debmalya Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
3245 - BCR-ABL transcript variant’s significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country
Presenter: Siva Prasad
Session: Poster Display session 1
Resources:
Abstract